• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Real World Evidence of Sustained Improvements Following Percutaneous PNS: A Retrospective Cross-Sectional Follow-Up Survey

August 8, 2021

The SPRINT PNS System provides peripheral nerve stimulation treatment percutaneously for up to 60 days. SPRINT PNS has been shown to provide a majority of patients with sustained pain relief following up to 60-days of PNS treatment in various prospective studies across multiple pain indications.  For patients with sustained pain relief, SPRINT PNS may prevent the need for implantation of a permanent neurostimulation system.

With the growing use of the SPRINT PNS System in broader clinical practice, leading interventional pain physicians and clinical researchers explored the effectiveness and long-term impact of this short-term PNS treatment.

Evaluating the Effectiveness and Long-Term Impact of 60-Day PNS Treatment for Pain Relief

Patients who previously received a 60-day PNS treatment were asked to participate in a retrospective, cross-sectional survey. This is the largest data set of real-world evidence regarding the effectiveness and long-term impact of the 60-day PNS treatment delivered by the SPRINT PNS System.

The survey results included the responses of 354 SPRINT PNS System patients who opted-in to provide data and who completed treatment between March 2018 and December 2020. (A total of 2,028 patients were offered the chance to participate in the survey). Among the survey respondents, the most common pain treatment areas included pain in the low back, shoulder, knee, and foot/ankle regions.

The survey assessed the following:

  • Worst pain (Brief Pain Inventory Question #3, BPI-3)
  • Average pain (BPI-5)
  • Percent pain relief (BPI-8)
  • Changes in medication usage
  • Patient Global Impression of Change (PGIC)

In accordance with recent evidence-based guidance regarding the importance of evaluating multiple dimensions of potential benefit in patients (e.g., pain intensity, quality of life, physical function) responders were defined by reporting a ≥50% reduction in pain and/or clinically significant improvement in Quality of Life as assessed using the Patient Global Impression of Change (PGIC).

Survey Results Demonstrate Support for Short-Term PNS for Treating Various Pain Conditions with Sustainable Relief

The survey results demonstrated significant pain relief across a wide range of patients, consistent with previously published clinical studies assessing short-term percutaneous PNS.

Sustained Long-Term Improvements Reported in a Majority of Survey Respondents  

35% of Respondents Treated with Short-Term PNS Stopped or Reduced Opioid Usage

As mentioned above, the survey noted reductions in both opioid usage and gabapentinoid usage. More specifically at the time of the survey, 35 percent (n=56/160) of respondents who were using opioids at baseline stopped or reduced opioid usage, and 32 percent (n=58/183) of respondents who were using gabapentin had stopped or reduced gabapentin usage.

“These findings validate the potential of the SPRINT PNS System to provide relief that enables patients to reduce or stop opioid use,” said Nate Crosby, PhD, Sr. Research Project Manager at SPR Therapeutics.  “In the midst of the ongoing opioid crisis, physicians are in need of more minimally-invasive treatment options that can also be opioid-sparing. This real-world evidence supports that SPRINT can help fill that role.”

Conclusion: Real-world Evidence Provides Further Validation of Prior Research Regarding the Sustained Effects Following the 60-day Treatment Provided by the SPRINT PNS System

These survey findings present the largest body of real-world evidence to-date supporting the prolonged effectiveness of 60-day PNS treatment. The findings here are consistent with the outcomes previously published across multiple prospective clinical trials.  And the real-world data coupled with the published clinical trial outcomes support the use of a 60-day PNS treatment across a wide range of pain conditions in broader clinical practice.

“Demonstration of clinical trial outcomes that translate into broader clinical practice is important to validating the utility of pain treatments like the SPRINT PNS System, both to maximize patient benefit while ensuring that physicians know what to expect when they recommend SPRINT PNS to their patients,” said lead author Dr. Matthew Pingree.  “These survey results help us understand the benefits patients are receiving from 60-day PNS treatment in the real-world setting and corroborate peer-reviewed publications regarding clinical trials.”

Moreover, these data reveal the potential for short-term PNS to serve as a non-opioid (and potentially opioid-sparing) pain treatment option with the potential for sustained pain relief that may prevent the need for a permanently implanted system.

To view other clinical outcomes and references, click here.

View more articles and news here.


The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.  

Important safety & risk information: https://bit.ly/2FU92NH


Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: 60-day percutaneous PNS, Back Pain, Chronic Pain, drug-free, PNS, reduced opioids, research, SPRINT PNS, SPRINT PNS System
Previous Post:Maria Bennet EY Entrepreneur of the Year in East Central RegionSPR Therapeutics CEO Maria Bennett Selected as Winner of EY Entrepreneur of the Year in East Central Region
Next Post:Patients Prefer Temporary PNS Treatment for Chronic Back Pain Over RFA and More Invasive Neurostimulation Options Survey Finds

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Pain Medicine News Features SPRINT® PNS System Real-World Survey Outcomes

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

NANS 26th Annual Meeting – Las Vegas, NV

Sprint Regional Lab – Jacksonville

Sprint Regional Lab – Chicago

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo